注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Scholar Rock Holding Corp是一家專注於發現和開發治療嚴重疾病的藥物的生物製藥公司。該公司的候選產品包括apitegromab,apitegromab是一種激活潛在肌生長抑制素的抑製劑,用於治療脊髓性肌萎縮(SMA),並用於治療其他肌生長抑制素相關疾病。其候選產品還包括SRK-181,SRK-181是一種激活潛在轉化生長因子β1(TGFβ1)的抑製劑,用於治療抗PD-(L)1抗體療法耐藥的癌症。其選擇性抑製劑激活轉化生長因子β(TGFβ),用於治療纖維化疾病。它正在推進多種抗體圖譜的產品候選選擇,包括在纖維化細胞外基質中選擇性抑制潛在TGFβ1激活的抗體,以及避免干擾免疫系統細胞呈現的TGFβ1的抗體。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
David L. Hallal | 55 | 2017 | Independent Chairman of the Board |
Lynn Sakai | - | - | Member of Scientific Advisory Board |
Kristina M. Burow | 49 | 2014 | Independent Director |
Akshay K. Vaishnaw | 59 | 2014 | Independent Director & Member of Scientific Advisory Board |
Jeffrey S. Flier | 74 | 2016 | Independent Director & Member of Scientific Advisory Board |
Joshua Reed | 49 | 2021 | Independent Director |
Timothy A. Springer | 74 | 2012 | Member of Scientific Advisory Board |
Michael Gilman | 67 | 2013 | Independent Director & Member of Scientific Advisory Board |
Leonard I. Zon | - | - | Member of Scientific Advisory Board |
Scott L. Friedman | - | - | Member of Scientific Advisory Board |
Barry S. Coller | - | - | Member of Scientific Advisory Board |
Joan Massague | 69 | - | Member of Scientific Advisory Board |
Daniel B. Rifkin | - | - | Member of Scientific Advisory Board |
Amir H. Nashat | 49 | 2012 | Independent Director |
Shelia M. Violette | - | - | Member of Scientific Advisory Board |
Srinivas Akkaraju | 54 | 2022 | Independent Director |
Richard Brudnick | 66 | 2023 | Independent Director |
Jay T. Backstrom | 68 | 2022 | President, CEO & Director |
Katie Peng | 53 | 2024 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核